CN113966221B - 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途 - Google Patents

合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途

Info

Publication number
CN113966221B
CN113966221B CN202080034343.3A CN202080034343A CN113966221B CN 113966221 B CN113966221 B CN 113966221B CN 202080034343 A CN202080034343 A CN 202080034343A CN 113966221 B CN113966221 B CN 113966221B
Authority
CN
China
Prior art keywords
cancer
virus
oncolytic virus
replicon rna
synthetic oncolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080034343.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113966221A (zh
Inventor
D·J·欧文
K·D·维特鲁普
R·维斯
Y·栗
N·莫明
Y·董
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of CN113966221A publication Critical patent/CN113966221A/zh
Application granted granted Critical
Publication of CN113966221B publication Critical patent/CN113966221B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080034343.3A 2019-03-08 2020-01-10 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途 Active CN113966221B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815611P 2019-03-08 2019-03-08
US62/815,611 2019-03-08
PCT/US2020/013069 WO2020185293A1 (en) 2019-03-08 2020-01-10 Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

Publications (2)

Publication Number Publication Date
CN113966221A CN113966221A (zh) 2022-01-21
CN113966221B true CN113966221B (zh) 2026-03-31

Family

ID=69526302

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080034343.3A Active CN113966221B (zh) 2019-03-08 2020-01-10 合成溶瘤lnp复制子rna和用于癌症免疫治疗的用途

Country Status (19)

Country Link
US (3) US11717548B2 (enExample)
EP (2) EP3934673B1 (enExample)
JP (2) JP7561134B2 (enExample)
KR (2) KR20250171410A (enExample)
CN (1) CN113966221B (enExample)
AU (1) AU2020233788A1 (enExample)
BR (1) BR112021017637A8 (enExample)
CA (1) CA3132714A1 (enExample)
CO (1) CO2021013417A2 (enExample)
DK (1) DK3934673T3 (enExample)
ES (1) ES3066636T3 (enExample)
FI (1) FI3934673T3 (enExample)
IL (1) IL285963A (enExample)
MX (1) MX2021010808A (enExample)
MY (1) MY207334A (enExample)
PH (1) PH12021552145A1 (enExample)
PT (1) PT3934673T (enExample)
SG (1) SG11202109514VA (enExample)
WO (1) WO2020185293A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
KR20250171410A (ko) * 2019-03-08 2025-12-08 메사추세츠 인스티튜트 오브 테크놀로지 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
IL316186A (en) 2022-04-26 2024-12-01 Strand Therapeutics Inc Lipid nanoparticles containing Venezuelan equine encephalitis (VEE) replicon and uses thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
JP2026502453A (ja) * 2023-01-12 2026-01-23 バヴァリアン・ノルディック・アクティーゼルスカブ がんワクチンのための組み換え改変ｓａＲＮＡ（ＶＲＰ）
WO2024211865A2 (en) * 2023-04-07 2024-10-10 Omega Therapeutics, Inc. Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery
CN118147171B (zh) * 2024-03-08 2024-12-06 上海复诺健生物科技有限公司 具有增强的外源基因表达水平的自扩增mRNA核酸序列
KR20260046366A (ko) 2023-07-25 2026-04-07 스트랜드 세러퓨틱스 인코포레이티드 마이크로 rna 비표적화 센서를 포함하는 폴리뉴클레오타이드 및 이의 용도
WO2025087372A1 (zh) * 2023-10-27 2025-05-01 上海元宋生物技术有限公司 溶瘤病毒及其用途
CN119479778B (zh) * 2024-10-16 2025-04-25 北京悦康科创医药科技股份有限公司 一种lnp转染效率预测模型构建方法及装置
CN121081290B (zh) * 2025-11-12 2026-03-10 佑嘉(杭州)生物医药科技有限公司 一种毛囊靶向递送系统及生发防脱化妆品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710079A (zh) * 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
CN117120446A (zh) * 2021-02-12 2023-11-24 俄亥俄州创新基金会 糖衍生的脂质纳米材料及其用途
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法
CN117897494A (zh) * 2021-07-09 2024-04-16 瑞普利科特生物科学公司 经修饰的东方马脑炎病毒、自复制rna构建体及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
US11291635B2 (en) * 2010-07-06 2022-04-05 Glaxosmithkline Biological Sa Virion-like delivery particles for self-replicating RNA molecules
CA2841047A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
WO2014089061A1 (en) * 2012-12-03 2014-06-12 Yasuko Rikihisa Ehrlichial invasin for immunization, diagnosis, and cell delivery
CN107072946B (zh) * 2014-09-05 2022-01-11 诺华股份有限公司 用于递送活性剂的脂质和脂质组合物
RU2739794C2 (ru) * 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
WO2016187531A1 (en) * 2015-05-21 2016-11-24 Ohio State Innovation Foundation Benzene-1,3,5-tricarboxamide derivatives and uses thereof
KR20250171410A (ko) * 2019-03-08 2025-12-08 메사추세츠 인스티튜트 오브 테크놀로지 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710079A (zh) * 2020-07-24 2023-09-05 斯特兰德生物科技公司 包含经修饰的核苷酸的脂质纳米颗粒
CN117120446A (zh) * 2021-02-12 2023-11-24 俄亥俄州创新基金会 糖衍生的脂质纳米材料及其用途
CN117897494A (zh) * 2021-07-09 2024-04-16 瑞普利科特生物科学公司 经修饰的东方马脑炎病毒、自复制rna构建体及其用途
CN117180454A (zh) * 2022-05-16 2023-12-08 上海行深生物科技有限公司 含有自复制rna分子和脂质纳米颗粒递送载体的组合物及其制备方法

Also Published As

Publication number Publication date
BR112021017637A8 (pt) 2022-08-16
KR20250171410A (ko) 2025-12-08
WO2020185293A1 (en) 2020-09-17
KR102889984B1 (ko) 2025-11-25
DK3934673T3 (da) 2026-04-07
US20200281994A1 (en) 2020-09-10
PH12021552145A1 (en) 2022-08-31
ES3066636T3 (en) 2026-05-13
BR112021017637A2 (enExample) 2021-11-09
SG11202109514VA (en) 2021-09-29
CN113966221A (zh) 2022-01-21
FI3934673T3 (fi) 2026-03-31
CA3132714A1 (en) 2020-09-17
MX2021010808A (es) 2021-12-15
MY207334A (en) 2025-02-19
KR20220006041A (ko) 2022-01-14
US20240024394A1 (en) 2024-01-25
US20260061013A1 (en) 2026-03-05
CO2021013417A2 (es) 2022-01-17
AU2020233788A1 (en) 2021-10-07
PT3934673T (pt) 2026-04-07
JP7561134B2 (ja) 2024-10-03
EP3934673A1 (en) 2022-01-12
US12383589B2 (en) 2025-08-12
JP2022524391A (ja) 2022-05-02
IL285963A (en) 2021-10-31
EP4729621A2 (en) 2026-04-22
US11717548B2 (en) 2023-08-08
EP3934673B1 (en) 2026-01-07
JP2025011109A (ja) 2025-01-23

Similar Documents

Publication Publication Date Title
KR102889984B1 (ko) 합성 종양용해성 lnp-레플리콘 rna 및 암 면역요법을 위한 용도
AU2023214288A1 (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
KR20180097631A (ko) 핵산을 와우 및 전정 세포에 전달하기 위한 물질 및 방법
AU2016214301B2 (en) Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
KR101255419B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 신규 백신
KR20210043574A (ko) 푸소좀 조성물 및 이의 용도
CN113950526A (zh) 通过靶向体内表观遗传阻遏实现的持久镇痛
CN110856724A (zh) 包含核酸及car修饰的免疫细胞的治疗剂及其应用
JP7644007B2 (ja) 第ｉｘ因子を発現するレンチウイルスベクターの使用
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
RU2771383C2 (ru) Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения
CN114008209A (zh) Aav介导的枫糖尿症(msud)基因疗法
KR20200089289A (ko) 비골수제거 골수 재건을 위한 방법 및 조성물
Gunnels et al. Elucidating design principles for engineering cell‐derived vesicles to inhibit SARS‐CoV‐2 infection
CN112725344B (zh) 密码子优化的smn1基因、腺相关病毒表达质粒及基因药物
CN108379597B (zh) 一种基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
CN106687592A (zh) 一种重组质粒、其构建的重组疟原虫及其应用
JP5846650B2 (ja) ベクター産生型腫瘍標的細胞
CN107760680B (zh) 特异性靶向TIM-3基因的sgRNA和特异性敲除TIM-3基因的方法
KR102679920B1 (ko) 모노머형 스트렙타비딘을 발현하는 균주 및 비오틴화된 화합물을 포함하는 암 세포 표적용 조성물
RU2809724C2 (ru) Синтетический онколитический lnp-репликон рнк и применения для иммунотерапии злокачественных опухолей
CN117795086A (zh) 用于枫糖尿症(msud)中bcaa调节的基因疗法
CN112342231A (zh) 一种不耐热ung融合蛋白的重组载体及表达纯化方法
CN108159434B (zh) 一种基因载体及其用于治疗青光眼的基因治疗药物
Yousefpour et al. Engineering gene expression dynamics via self-amplifying RNA with drug-responsive non-structural proteins

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant